Therefore, in this meta-analysis, we aimed to know the exact prevalence of KRAS, GNAS, and RNF43 mutations in IPMN patients, and the difference between the frequency of these mutant genes in pancreatic cystic lesions. This evidence concerns the gene GNAS and pancreatic intraductal papillary-mucinous neoplasm.